

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 10, 2020**

**Zymeworks Inc.**  
(Exact name of registrant as specified in its charter)

**British Columbia, Canada**  
(State or other jurisdiction  
of incorporation)

**001-38068**  
(Commission  
File Number)

**47-2569713**  
(IRS Employer  
Identification No.)

**Suite 540, 1385 West 8th Avenue, Vancouver, British Columbia,  
Canada**  
(Address of principal executive offices)

**V6H 3V9**  
(Zip Code)

**(604) 678-1388**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                          | Trading<br>Symbol(s) | Name of each exchange<br>on which registered |
|--|----------------------|--|
| <b>Common Shares, no par value per share</b> | <b>ZYME</b>          | <b>New York Stock Exchange</b>               |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## ITEM 7.01 REGULATION FD DISCLOSURE

On November 10, 2020, Zymeworks Inc. (the “Zymeworks”) issued a press release announcing that management will participate in four upcoming virtual investor conferences:

- Stifel’s 2020 Virtual Healthcare Conference is scheduled for November 16-18, 2020. Zymeworks is presenting on Tuesday, November 17, 2020 at 4:40 p.m. ET.
- Jefferies’ Virtual London Healthcare Conference is scheduled for November 17-19, 2020. Zymeworks is presenting on Wednesday, November 18, 2020 at 11:25 a.m. ET (4:25 p.m. GMT).
- Wolfe’s 2020 Virtual Healthcare Conference is scheduled for November 18-19, 2020. Zymeworks is presenting on Thursday, November 19, 2020 at 2:20 p.m. ET.
- SVB Leerink’s Oncology Day is scheduled for November 19, 2020. Zymeworks will be participating in conference; there is no public presentation.

On November 10, 2020, this press release was filed with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at [www.sedar.com](http://www.sedar.com). A copy of this press release is attached as Exhibit 99.1 hereto.

The information provided under this Item (including Exhibit 99.1, attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

## ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

### (d) Exhibits

| <u>Exhibit No.</u> | <u>Description</u>   |
|--------------------|--|
| 99.1               | <a href="#">Press Release dated November 10, 2020.</a>               |
| 104                | Cover Page Interactive Data File (embedded as Inline XBRL document). |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

***ZYMEWORKS INC.***

\_\_\_\_\_  
(Registrant)

Date: November 10, 2020

By: /s/ Neil A. Klompas

Name: Neil A. Klompas

Title: Executive Vice President, Business Operations and Chief Financial Officer



### Zymeworks to Present at Upcoming Investor Conferences

**Vancouver, Canada (November 10, 2020)** – Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in four upcoming virtual investor conferences.

- Stifel’s 2020 Virtual Healthcare Conference is scheduled for November 16-18, 2020. Zymeworks is presenting on Tuesday, November 17, 2020 at 4:40 p.m. ET.
- Jefferies’ Virtual London Healthcare Conference is scheduled for November 17-19, 2020. Zymeworks is presenting on Wednesday, November 18, 2020 at 11:25 a.m. ET (4:25 p.m. GMT).
- Wolfe’s 2020 Virtual Healthcare Conference is scheduled for November 18-19, 2020. Zymeworks is presenting on Thursday, November 19, 2020 at 2:20 p.m. ET.
- SVB Leerink’s Oncology Day is scheduled for November 19, 2020. Zymeworks will be participating in conference; there is no public presentation.

Interested parties can access a live webcast of the presentations via a link from Zymeworks’ website at <http://ir.zymeworks.com/events-and-presentations>, which will also host recorded replays available afterwards.

### About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody currently in a registration-enabling clinical trial for refractory HER2+ biliary tract cancer as well as several Phase 2 clinical trials for HER2+ gastroesophageal and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit [www.zymeworks.com](http://www.zymeworks.com).

### Contacts:

Investor Inquiries:  
Ryan Dercho, Ph.D.  
(604) 678-1388  
[ir@zymeworks.com](mailto:ir@zymeworks.com)

Tiffany Tolmie  
(604) 678-1388  
[ir@zymeworks.com](mailto:ir@zymeworks.com)

Media Inquiries:  
Mary Klem  
(604) 678-1388  
[media@zymeworks.com](mailto:media@zymeworks.com)